In 2020, the sales value of Pregabalin in the Chinese market is approximately CNY186 million. The CAGR in sales value of Pregabalin from 2016 to 2020 is 40.55%.

Pregabalin is an ion channel modulator used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. Its product, LYRICA was originally developed by Pfizer Ltd. LYRICA was launched in China in 2010 and was approved for the treatment of post-herpetic neuralgia. In 2018, it was approved for fibromyalgia indication. Subsequently, some generic drugs of Pregabalin were launched in China one after another.

In 2019, Pregabalin (trade name: Laireike) produced by Chongqing Saiwei Pharmaceutical was approved for the treatment of adult partial epilepsy, adding a new indication for Pregabalin in the Chinese market. By 2020, Pregabalin has been included in China’s Class B medical insurance, and there are three manufactures in the Chinese market, of which Pfizer Ltd is the main manufacture.

CRI expects that with the addition of new companies, the sales volume and market scale of Pregabalin in the Chinese market will continue to expand from 2021 to 2025. According to CRI’s market research, by the first half of 2021, there are more than 20 companies in China that are applying for Pregabalin generic drugs, including Jiangsu Hengrui Pharmaceutical Co., Ltd., Xuzhou Enhua Pharmaceutical Co., Ltd., and Sichuan Kelun Pharmaceutical Co., Ltd. In addition, China has approved the marketing of 3 indications of Pregabalin, and a total of 4 indications have been approved for marketing globally. Therefore, the number of indications of Pregabalin in China is likely to increase, and sales value and sales volume will increase in the future.

Topics Covered in Investigation Report on China’s Pregabalin Market 2021-2025

• -The impact of COVID-19 on China’s Pregabalin market
• – Sales value of China’s Pregabalin 2016-2020
• – Competitive landscape of China’s Pregabalin market
• – Prices of Pregabalin in China
• – Prices of Pregabalin in China by regions and manufacturers
• – Analysis on factors affecting the development of China’s Pregabalin market
• – Prospect of China’s Pregabalin market from 2021 to 2025

Investigation Report on Chinese Pregabalin Market, 2020-2024

The post Investigation Report on China’s Pregabalin Market 2021-2025 first appeared on CRI Report.

Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin.

In 2007, Pregabalin was approved by the FDA as the first drug to treat fibromyalgia syndrome. In 2012, Pregabalin was approved by the FDA to treat spinal cord injury (SCI)-related pains. In 2010, Lyrica was approved to enter China.

According to CRI, the sales value of Lyrica increased by more than 450 times from about CNY 200,000 in 2010 to over 90.74 million in 2018. Due to Lyrica’s success, many domestic manufacturers applied for Pregabalin production.

Chongqing Succeway Pharmaceutical Co., Ltd.’s Pregabalin (trade name: Lairuike) was put in the market after obtaining the production license in 2013 and is gradually taking market share from Pfizer. By sales value, in 2018, Pfizer’s Lyrica had a market share of approximately 77.13%, and the rest market share was captured by the products of Chongqing Succeway Pharmaceutical Co., Ltd.

It is estimated that Pfizer’s Lyrica will continue to dominate the Chinese market from 2020 to 2024 but its market share will decline because of the price competition of China-made Pregabalin.

According to CRI, there is a continuous rise in the number of people suffering from indications for Pregabalin. For example, the number of epileptics in China has exceeded 10 million and increases by 500 thousand every year. Therefore, Pregabalin has a bright prospect in China.

Topics Covered:
Development environment of Chinese Pregabalin market
Governmental approval of Pregabalin in China
Prices of Pregabalin in China
Major Pregabalin manufacturers in China
Factors influencing the development of Chinese Pregabalin market
Prospects of Chinese Pregabalin market

Investigation Report on China’s Pregabalin Market 2021-2025

The post Investigation Report on Chinese Pregabalin Market, 2020-2024 first appeared on CRI Report.

Investigation Report on Chinese Pregabalin Market, 2018-2022

The post Sample of Investigation Report on Chinese Pregabalin Market, 2018-2022 first appeared on CRI Report.

Topics Covered:
– Development environment of Chinese Pregabalin market
– Governmental approval of Pregabalin in China
– Prices of Pregabalin in China
– Major Pregabalin manufacturers in China
– Factors influencing the development of Chinese Pregabalin market
– Prospects of Chinese Pregabalin market

Related reports:

https://www.cri-report.com/product/investigation-report-on-chinas-pregabalin-market-2021-2025/

The post Investigation Report on Chinese Pregabalin Market, 2018-2022 first appeared on CRI Report.